SCHEMBL26818015

SCHEMBL26818015

C[C@@H]1Cc2ccccc2CN1C(=O)c1cccs1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 5/20 0.54
▸ HSD17B10 Q99714 2/20 0.54
▸ LMNA P02545 1/20 0.54
▸ ALOX15 P16050 1/20 0.54
▸ F10 P00742 1/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ NPC1 O15118 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.46
▸ OPRM1 P35372 1/20 0.45
▸ OPRD1 P41143 1/20 0.45
▸ OPRK1 P41145 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ CASP1 P29466 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ SLC18A3 Q16572 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26818011 0.83 F10 (0.46) TSHRHSD17B10LMNAALOX15F10
SCHEMBL3891473 0.79 HSD17B10 (0.75) TSHRHSD17B10LMNAALOX15SMN1; SMN2
SCHEMBL29409300 0.78 NR1D1 (0.67) TSHRHSD17B10F10ALDH1A1POLB
SCHEMBL28557927 0.78 NR1D1 (0.67) TSHRHSD17B10F10ALDH1A1POLB
SCHEMBL1690525 0.78 LMNA (0.54) LMNASMN1; SMN2ALDH1A1OPRM1OPRD1
SCHEMBL18970120 0.78 LMNA (0.54) LMNASMN1; SMN2ALDH1A1OPRM1OPRD1
SCHEMBL15355395 0.76 OPRM1 (0.49) LMNANPC1ALDH1A1OPRM1OPRD1
SCHEMBL20738534 0.76 NOTUM (0.56) ALDH1A1OPRM1OPRD1OPRK1POLB
SCHEMBL20738530 0.76 NOTUM (0.56) ALDH1A1OPRM1OPRD1OPRK1POLB
SCHEMBL419149 0.76 NOTUM (0.56) ALDH1A1OPRM1OPRD1OPRK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834450-B2 Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors Eil Therapeutics, Inc. (US) 2023-12-05 — — US disclosed
US-11834450-B2 Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors Eil Therapeutics, Inc. (US) 2023-12-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834450-B2 Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors BCL2, BCL2A1, BCL2L1 TSHR 3891/4885HSD17B10 621/4885LMNA 1943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback